17 profiles found

Dr Shweta Khandelwal is Head, Nutrition Research at the Public Health Foundation of India (PHFI), Delhi. She is a trained and experienced public health nutrition researcher working in the maternal child health and nutrition space in India for the last 17 years. Shweta teaches nutrition epidemiology especially in relation to the rising overweight-obesity, diet related non-communicable diseases and their risk factors among the Indian population. She has served on expert government panels on topics like oils and fats, sustainable healthy diets and combating high fat, sugar and salt in Indian population etc. As a Women Lift Health fellowship awardee, Shweta is a sincere advocate for gender equity and women empowerment especially in nutrition. She is also the Lead for capacity building initiatives in Public Health Nutrition at PHFI and CCDC. In addition to more than 80 peer reviewed articles in scholarly journals, she has contributed to more than 160 media pieces including 50 op-eds in leading international and national print and online platforms. Shweta has also won several prestigious awards, fellowships and grants in the area of nutrition and chronic diseases.

Sarah is a research fellow in social care at the LSE Care Policy and Evaluation Centre (CPEC) and a Policy Fellow embedded in the Strategy Team at the City Intelligence Unit at the Greater London Authority. She is part of CPEC’s   partnership   in the NIHR Applied Research Collaboration North Thames, as a member of the ARC-NT’s Research Partnership Team. She is a mixed-methods researcher with experience in complex evaluations in mental health, social care and health services. Sarah holds a BSc (Joint Honours) in Biology and Management as well as an MPH and a PhD from Imperial College London. She has previously worked in research roles as a mixed-methods research fellow for the NIHR Applied Research Collaboration North Thames within the Department of Applied Health Research at UCL, evaluating the national "Getting It Right First Time" (GIRFT) programme, and at the Royal College of Psychiatrists on the randomised controlled evaluation of Low Secure Services (eLSU) study within the College Centre for Quality Improvement.

I have several academic qualifications in the field of the international political economy of trade and development, namely, a PhD from the London School of Economics (LSE) with a dissertation in international political trade, and two Masters in Development Management (LSE), and International Affairs (Washington University in St. Louis) with concentrations in the political economy of development and development policy and international affairs. I have worked for international organizations (United Nations, World Bank) and think tanks on social and economic policy issues. In addition, I have a medical doctor (MD) degree and a second PhD in biomedical sciences. I have researched, produced, and delivered consulting reports on socio-economic policy issues for international organizations . As part of my work for the United Nations Economic and Social Commission for Asia Pacific (UN-ESCAP), the largest policy think tank in the region, and the World BankI wrote status evaluations, good practices, and policy reports for developing governments in the region on the liberalization of trade of goods and services and other macroeconomic and development issues. I consulted and wrote reports for both international organizations on trade and industrial policy and the impact of investment liberalization in Southeast Asia. I led and collaborate on UN-ESCAP projects that analyzed policy options to strengthen and finance development projects. I have consulted for United Nations and the World Health Organization on domestic policies and recommendations for regional cooperation on R&D, manufacturing, and trade for vaccines in Asia Pacific. I also consulted for the Overseas Development Institute (ODI), on Public Expenditure Management in developing countries. I have designed, managed, and evaluated development policy projects in very different contexts and for diverse types of clients. As part of my work for international organizations, I provided policy advisory services and/or capacity building to policy makers and government officials in developing countries.  During my tenure at the UN, I participated in the organization of high-level inter-governmental and government-business conferences . I have also conducted academic research to identify the political and economic variables that drive trade liberalization and the integration of countries into the international economy, as well as to investigate how this integration (or lack thereof) affects economic policy, the operations of firms in regional production networks, as well as the relations between and among states and firms. My analyses use both qualitative and quantitative methodologies and my industry focus on the automotive, biotechnology and pharmaceutical, and processed food industries. My research has been published in World Economy (37:1612-1633), Review of International Political Economy (RIPE) (23:379-417), and RIPE (doi: 10.1080/09692290.2021.1892796). My earlier academic articles analyzed the political dynamics in participatory governance initiatives in Latin America (Urban Studies, 48:1945-67), policy options for financing infrastructure in China and India (Journal of Asian Public Policy 1:71-89). I also researched and started expert-level discussions on how the impacts of climate change on human health can contribute to international collective action (Development, 53:403-8; Bulletin WHO, 85:825-7).  My verbal communication skills are proven by the numerous presentations and invited lectures I delivered for different types of audiences: academics, government policymakers, and development practitioners. I possess more than 15 years of teaching experience in universities in the US, Europe, and Asia. In the areas of public policy and political economy, I have lectured on trade and development as part of visiting scholar posts in Europe and East Asia, and I have taught. I staffed, trained, and supervised my own research group (7-10 people) while networking with other teams. I have a highly successful record of securing research funding from government agencies and private foundations across Europe and the US.

Beth Kreling is a Senior Policy Fellow in the Department of Health Policy at the London School of Economics & Political Science (LSE). She is currently co-PI of the newly established   African Health Observatory Platform on Health Systems and Policies   (AHOP) and Deputy Chair of the LSE’s   Global Health Initiative   (GHI), an interdepartmental research unit. Beth has a background in international development and consultancy, with a regional focus on Africa. She has always worked at the nexus of research and policy, coordinating numerous multi-country research, development and consultancy projects both at LSE and previously. Whilst at LSE she has worked across the Department’s global health portfolio, establishing and managing the GHI and supporting a range of projects including leading a multi-partner, EU funded, public-private initiative   Big Data for Better Outcomes . Beth is currently the operational lead for the LSE team working on the African Health Observatory Platform (AHOP). Hosted by the WHO Regional Office for Africa (WHO AFRO), AHOP leverages existing national and regional collaborations to form a network of National Centres that currently include leading research institutions in Ethiopia, Kenya, Nigeria, Rwanda and Senegal. AHOP draws on support from a technical consortium including the European Observatory on Health Systems and Policies, LSE and national, regional and global partners. Before joining LSE, Beth worked for the Commonwealth Secretariat’s Health and Education Unit, engaging with stakeholders across Commonwealth governments, inter-governmental organisations and NGOs on education policy priorities. She continues to write occasionally on Commonwealth education topics. Prior to this she was Chief Operating Officer of education NGO Link Community Development International, where she oversaw operations and programme development in the UK and across five sub-Saharan African offices. Before moving into a development sphere, Beth spent a number of years as a political and economic risk consultant for strategy consultancy Oxford Analytica. She began her professional career in publishing as Assistant Editor for Pavilion and Collins & Brown.

Katy Footman is a mixed methods researcher with a technical focus on sexual and reproductive health. She has ten years of professional experience conducting research and translating evidence into programmes and policy.  Katy previously worked at MSI Reproductive Choices (formerly Marie Stopes International), the Public Health England Behavioural Science team, and the London School of Hygiene and Tropical Medicine (LSHTM). She consults for clients including the World Health Organization and Itad. Katy is currently completing a PhD in Demography and Population Studies from the London School of Economics (LSE) and she has Masters degrees in Health Policy, Planning and Financing from the LSE and LSHTM, and in Social Research Methods from the LSE.

Dr Charles Ebikeme is a Policy Officer in the Department of Health Policy. Charles is currently part of the LSE team working on the  African Health Observatory Platform on Health Systems & Policies (AHOP) . Hosted by the WHO Regional Office for Africa (WHO AFRO), AHOP leverages existing national and regional collaborations to form a network of National Centres that currently include leading research institutions in Ethiopia, Kenya, Nigeria, Rwanda and Senegal. AHOP draws on support from a technical consortium including the European Observatory on Health Systems and Policies, LSE and national, regional and global partners. Charles received his PhD in Parasitology from the University of Glasgow. His PhD focused on understanding how drugs work against parasites and how parasites become resistant to drugs. In the case of African trypanosomiasis, transport related phenomena have been central and a major research area has been associated with understanding drug resistance. His research investigated the inner workings of the parasite that causes African sleeping sickness and the development of novel treatments for the disease. He holds an MSc in Infectious Diseases from the London School of Hygiene and Tropical Medicine (LSHTM) and a BSc in Biochemistry from University College London. Prior to joining LSE, Charles worked at the intersection of research and policy, focusing on mainstreaming health into sustainable development topics such as climate change and urbanisation. He has managed global research programmes and spearheaded policy and advocacy initiatives globally.

I am a health economist with experience of both econometric and decision analytic modelling. My research focuses on health inequalities with a particular focus on the UK ad Indian health systems. 

Professor Joan Costa-Font works at LSE as a Professor of  Health Economics, and team leader of the ageing and health incentives unit (AHIL) in the Department of Health Policy where he is  Co-director of the MSc International Health Policy. Joan has been Harkness Fellow at Harvard University and currently, he is a CESifo and IZA network research fellow, and has been Harkness Fellow at Harvard University and visiting fellow at UCL, Boston College, Oxford University (IA) and the University of Munich (CES). Professor Costa-Font earned three undergraduate and research degrees, in economics, law and political science a master's degree in economic analysis from Universitat Pompeu Fabra, and an MSc (Econ) in international health policy (specialising in health economics and public economics). After completing a PhD in economics, in 2001 he earned a Marie Curie Postdoctoral Fellowship based at LSE and taught microeconomics and health economics as a tenured associate professor at the University of Barcelona before joining LSE in 2007, initially as a lecturer, and later as senior lecturer (2010) and then reader (2012). He has been a consultant to the WHO,  the World Bank, the Latin-American Development Bank, OECD, European Commission and private originations.  Expertise:  behavioural incentives; ageing, long-term care, health disadvantage; healthy lifestyles; preventative health care, health behaviours (smoking, obesity, sleep, food, exercise). LSE Consulting projects: Children's Wellbeing and Development Outcomes for Ages 5, 7 and 11, and their Predictors Public Health England, March 2016 - April 2018 Social Policy Reforms in the EU: A Cross-national Comparison BertelsmannStiftung, October 2015 A Common Disease with Uncommon Treatment: European Guideline Variations and access to innovative therapies for Rheumatoid Arthritis Policy Analysis Centre, July 2012 Measures to Promote the Situation of Roma EU Citizens in the European Union European Parliament - DG for Internal Policies, January 2011 Pharmaceutical Reimbursement Policy in Turkey New Hope in Health Foundation (SUVAK), September 2005 The Economic Impact of Pharmaceutical Parallel Trade in European Union Member States: A Stakeholder Analysis Johnson & Johnson, January 2004

Dr Panos Kanavos is Associate Professor in International Health Policy in the Department of Health Policy at London School of Economics and Political Science, Deputy Director at LSE Health and Programme Director of the Medical Technology Research Group (MTRG). Dr Kanavos has previously been Harkness Fellow in Health Care Policy in the Department of Ambulatory Care and Prevention, Harvard Medical School and has held visiting professor appointments at the University of Basel, the University of Delaware and the London School of Hygiene and Tropical Medicine. He is an economist by training, and teaches health economics, pharmaceutical economics and policy, health care financing, health care negotiations, and principles of health technology assessment. He has acted as an advisor to a number of international governmental and non-governmental organizations, including the European Commission, the European Parliament, the World Bank, the World Health Organization, the Organization for Economic Co-operation and Development (OECD), the American Association for Retired Persons, and Ministries of Health of over 28 transition, emerging and developing countries. Current research Panos' research interests include comparative health policy and healthcare reform, pharmaceutical economics and policy from a developed and developing country perspective, quality and access in healthcare, and socio-economic determinants of health. He leads the activities of MTRG, which is a research group comprising of 13 researchers and concentrates on interdisciplinary and comparative policy research on medical technologies. The group conducts research on a number of research streams. As part of its activities, MTRG is currently co-ordinating the activities of the IMPACT HTA consortium, an EU H2020 grant, and has previously coordinated the activities of key research grants on Health Technology Assessment (Advance HTA project), on  Chronic Disease  and a component of  Best Practices in Rare Diseases . It has conducted research under the auspices of and participated in the European Medicines Information Network (EMI-net) and the  network for the study of rare diseases . It also coordinates the activities of The Patient Academy, an initiative between academia, health care regulatory agencies and patient groups. Expertise:  health economics; health technology assessment; economics of medical technologies; pharmaceuticals; disease management; quality of care LSE Consulting projects: Access to medicines in Europe: Delays and challenges for timely patient access MSD, November 2021 The Role of Virtual Health Care and the Pharmaceutical Sector in Improving Population Health Sanofi, June 2021 Severe Asthma Healthcare Policy Audits AstraZeneca, May 2021 Predictive Analytic Tools and Value-based Health Care Takeda, February 2021 Access to Personalised Oncology in Europe European Federation of Pharmaceutical Industries and Associations (EFPIA), November 2020 Latin America Healthcare System Overview: A comparative analysis of fiscal space in healthcare F. Hoffmann-La Roche AG, August 2019 Pharmaceutical Policy in China Gilead Sciences, May 2019 Pharmaceutical Pricing and Reimbursement in the Middle East and North Africa Region: A Mapping of the Current Landscape and Options for the Future Pharmaceutical Research and Manufacturers of America (PhRMA), November 2018 Changing paradigms in the management of Multiple Sclerosis F. Hoffmann - La Roche, November 2018 Accelerated Approval and Access Schemes: A mapping of policies across the globe and the impact of accelerated approval on the HTA of new oncology medicines AstraZeneca, May 2017 – July 2018   European survey on the use of Real World Evidence F. Hoffmann - La Roche, January 2017 - May 2018 The use of Real World Evidence – Opportunities for Europe F. Hoffmann - La Roche, November 2016 - January 2018 External Reference Pricing within and across countries Pfizer, January 2016 - November 2017 Improving Outcomes for People with Multiple Sclerosis (MS): Review of the International MultiPlE Sclerosis Study (IMPrESS) findings F. Hoffmann - La Roche, October 2017 Understanding the Hepatocellular Carcinoma (HCC) Patient Landscape: Results of the first global survey of people living with HCC Sirtex Medical, January 2017 – November 2017 Study on impact analysis of Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA) Sogeti, August 2017 Controlling Pharmaceutical Expenditure and Improving Efficiency within the Spanish Pharmaceutical Market: Macro- and micro-level policy approaches Gilead Sciences, June 2017 Tender Loving Care? Purchasing Medicines for Continuing Therapeutic Improvement and Better Health Outcomes Baxalta (part of Shire), November 2016 Towards better outcomes in multiple sclerosis by addressing policy change: The International MultiPlE Sclerosis Study (IMPrESS) F. Hoffmann-La Roche, March 2016 The Value of Early Diagnosis and Treatment in Parkinson’s disease European Brain Council, March 2016 Cost and Impact of Non-Treating Severe Mental Illnesses (SMIs): The Case Study of Schizophrenia European Brain Council, January 2015 The Transatlantic Trade and Investment Partnership: International Trade Law, Health Systems, and Public Health European Public Health Alliance (EPHA), January 2015 Diabetes Expenditure, Burden of Disease and Management in 5 EU Countries Novo Nordisk, January 2012 The Role of Funding and Policies on Innovation in Cancer Drug Development Novartis Pharma AG, September 2009 Pharmaceutical Reimbursement Policy in Turkey New Hope in Health Foundation (SUVAK), September 2005 The Economic Impact of Pharmaceutical Parallel Trade in European Union Member States: A Stakeholder Analysis Johnson & Johnson, January 2004

Alexander is attached to the  Department of Media and Communications  at LSE, where he undertakes research, teaching and other activities. He also teaches on LSE Custom Programmes and the Masterclasses in Social Science, in the UK and Spain. Alexander brings extensive previous international career experience including at C-suite level to the LSE in digital, internet, e-commerce, FMCG, media & broadcasting, aerospace and banking including financial crime/AML. He advises organisations and government and undertakes research in digital, media and communications, socioeconomic analysis, health economics, productivity and management practices, as well as teaching in these and other areas. Many of Alexander's findings are high profile with a number of reports amongst the most downloaded from the LSE including 'The British Cycling Economy' with around 22,000 downloads.  Others such as the ‘Sky High Economics’ report trilogy is recognised as leading industry analysis and has provided the content that has won three international communications awards including the  B2B Campaign Award for Ogilvy-Inmarsat at the International Content Marketing Awards 2018, a SABRE 2020 PR Award beating 6,000 global entries, and the prestigious  2020 CIPR Award in PR in the Transport segment. The 2020 released report quantifying the socioeconomic impact of road traffic accidents globally in children remains one the most detailed reports of its kind and was launched by HM Queen Letizia of Spain in conjunction with the UN and UNICEF in 2020. Alexander continues to undertake detailed research pre-and post the pandemic on the transformative role of digitalisation and how this affects cohort behaviour, social, and consumer activities and organisational responses including defining whether entities are 'hiders, thrivers or survivors'. Expertise: digital; e-commerce; internet; new media; broadcasting; cohort behaviour (social media, digital and non-digital); information systems, cloud; management practices and productivity; innovation; socioeconomic analysis; health, injury and transport economics; financial crime/AML; aerospace. LSE Major Research and Projects (public domain): Digitalisation in the New Normal: Empowering Generation Z and Millennials to Deliver Change .    Freshworks, November 2022 New Era In Experience Adobe, April  2021 Sky High Economics - Chapter Three: Capitalising on changing passenger behaviour in a connected world Ogilvy / Inmarsat Aviation, September 2019 Sky High Economics - Chapter Two: Evaluating the Economic Benefits of Connected Airline Operations Ogilvy / Inmarsat Aviation, June 2018 Sky High Economics - Chapter One: Quantifying the commercial opportunities of passenger connectivity for the global airline industry Ogilvy / Inmarsat Aviation, September 2017 Managing Every Mile:  How to deliver greater return on investment from Travel and Expense Amadeus, September 2017 Industrial Strategy in Practice: Innovation and Management Best Practices in the Automobile, Energy and Aerospace Clusters in Bizkaia May 2017 The Power of Productivity Vodafone, December 2016 Socioeconomic Value of Mission Critical Mobile Applications for Public Safety in the UK: 2x10MHz in 700MHz Motorola, May 2013 Socioeconomic Value of Mission Critical Mobile Applications for Public Safety in the EU: 2x10MHz in 700MHz in 10 European Countries Motorola, March 2013 The British Cycling Economy: ‘Gross Cycling Product’ Report British Cycling/BSkyB, September 2011 The Olympic Cycling Effect British Cycling/BSkyB, November 2012 The Impact of Road Traffic Accidents with Child Victims Abertis in conjunction with United Nations Collaboration Group for Road Safety and UNICEF,  January 2020 The Transformative Effect of Cloud on Firm Productivity and Performance: Defining the Benefits and Impact of Cloud as a 21st Century Digital Enabler Amazon Web Services, March 2019 Confident Collaboration in the Cloud Navisite, June 2018 Modelling the Cloud Employment effects in two exemplary sectors in The United States, the United Kingdom, Germany and Italy Microsoft, January  2012 Innovation, Skills Development and Labour: A European Perspective Microsoft, June 2007 Size and Health of the UK Space Industry : Economic and qualitative analysis and input into the 2021 UK Space Agency's survey and report quantifying the size and health of the UK Space Sector and also acting as sector and economic SME. BryceTech, UK Space Agency, 2021. Socioeconomic Impact Analysis- Rolls Royce Motor Cars : Quantifying the socioeconomic contribution (Gross Value Added) and employment effect of one of the UK's and the world's most iconic motor vehicle brands including detailed modelling and report for use with government and other audiences with significant media coverage generated . Rolls Royce Motor Vehicles, 2022. LSE Major Research and Projects (not public-domain): Development of an Index of 'Alpha' Characteristics of Success for Target Firms.   Developing index encompassing qualitative and quantitative factors that can assign a rating reflecting the prevalence of 'alpha' success factors to enable a comparative assessment of the attraction of target prospects for MBOs and other off-market transactions. Confidential, UK/US Venture Capital Firm Identity Capital: Monetising the value of Identity.   Developing algorithm and methodology to quantify the value of social and individual data (business and personal) for GB Group to define a value for 'identity capital' for entities and individuals based on the nature of available data and other factors in an increasingly digitalised identity environment. GB Group Quantifying the Socioeconomic Contribution of Warner Brothers UK:    Deep and wide analysis of Warner Brothers' complex UK operations to define its socioeconomic contribution  to the UK economy including its direct, indirect and induced contribution. Warners Brothers UK Quantifying the Socioeconomic Contribution of One of the UK's Largest Sports and Leisure Events Organisations.  Detailed ground-up analysis and extensive demand and economic modelling of the integrated entity to define its socioeconomic direct, indirect and induced contribution both to the local and national economy. Confidential- Major leading UK leisure and sports organisation Revised Regulatory Impact Analysis of FAA Part 117 Final Rule: Flight Crew Member Duty Rest Requirements ('Cargo Carve Out'):  Analysis of original FAA decision assessing the carve out for the air cargo sector including deep analysis of key variables utilised for the decision.  Confidential- US/UK Air Transport organisation Economic Impact Assessment - UK Spaceport:  Input into the economic analysis of a UK spaceport including deep assessment of direct, indirect and induced contribution and acting as sector and economic SME. Confidential- UK organisation . Cybercrime and Cybersecurity:  Assessing major trends, risks and mitigation in online digital services and by cohorts and defined segmentation, with recommended best-practices by major geographic regions . Confidential- Global telecom manufacturer: equipment, hardware, software and security

Martin Knapp is Professor of Health and Social Care Policy at the Department of Health Policy and Director of NIHR School for Social Care Research. He has also been Director of the NIHR School for Social Care Research since 2009 and conducts research at the Care Policy and Evaluation Centre (CPEC; formerly PSSRU). His current research emphases are primarily dementia, child and adult mental health, autism and long-term social care; much of his work has an economic focus, and in all of it he seeks to tease out the policy implications. He has published more than 500 peer-review journal papers and 15 books. His work has had numerous impacts on policy and practice in these areas. Expertise:  community care policy; dementia; health economics; health policy; long-term care; mental health; mental health economics; social services; social care

Alex Gillespie is a Professor in the Department of Psychological and Behavioural Science  at LSE and Editor of  Journal for the Theory of Social Behaviour . He has published six books and over a hundred papers. He is an expert on communication, divergences of perspective, misunderstandings, trust and listening. He has been involved in developing several tools, including: the Interpersonal Perception Toolkit for Communication Disorders, GUIDE, and the Healthcare Complaints Analysis Tool. Expertise:  behavioural science; fieldwork in health care; psychological science

Dr Aris Angelis is an Assistant Professor in Health Economics with the Department of Health Services Research and Policy at the London School of Hygiene and Tropical Medicine (LSHTM), and a Visiting Fellow with the Department of Health Policy at LSE. Prior joining LSHTM, Aris worked for 10 years with the Medical Technologies Research Group at LSE Health. Aris’ academic interests are in the areas of pharmaceutical policy, health technology assessment (HTA), and drug regulation, with a lot of his work focusing on methodological research around the evaluation of new medical technologies. At LSHTM, Aris is leading the development of a research programme for assessing the value of new oncology products at an early stage by applying decision analytic modelling techniques, while collaborating with the Center for Health Policy & Outcomes at the Memorial Sloan Kettering Cancer Center. At LSE, Aris is involved with the EU funded project IMPACT-HTA, co-leading the research activities of WP7 on multi-criteria value methods where he is working towards a new value framework for medicines in collaboration with different HTA bodies. He is also involved in a project initiative with the European Society for Medical Oncology (ESMO), co-leading research activities towards the development of a new value framework for cancer medicines, involving large-scale preference elicitation studies with different stakeholders. Aris has undertaken contracted research, training and advisory work for the European Commission, the World Health Organisation, national health ministries and various biopharmaceutical organisations. Aris received his Doctor of Philosophy (PhD) in Pharmaceutical Policy and Economics from the Department of Social Policy (LSE Health) at LSE. His PhD investigated the development and application of a methodological framework based on Multiple Criteria Decision Analysis (MCDA) for assessing the value of new medical technologies in the context of HTA, to inform resource allocation decisions and incentivise socially desirable R&D investments. He also holds an MSc in International Health Policy from the LSE, an MSc in Biopharmacy from King’s College London and a BSc in Biochemistry from Imperial College London. Expertise:  access to medicines; biomedical innovation; decision analysis; economic evaluation; health economics; health policy; health technology assessment; multiple criteria decision analysis; pharmaceutical economics; pharmaceutical policy; pharmaceutical regulation; priority setting; value assessment

Ken Shadlen is Professor of Development Studies in the Department of International Development of the London School of Economics and Political Science. Ken works on the comparative and international political economy of development, with a focus on understanding variation in national policy responses to changing global rules. In recent years Ken’s research has focused largely on the global and cross-national politics of intellectual property (IP). He is interested in the implications that the new global IP regime presents for late development, and the various ways that international norms for IP affect national practices. His book,  Coalitions and Compliance: The Political Economy of Pharmaceutical Patents in Latin America , analyzes differences in how countries introduced pharmaceutical patents in the 1990s and then subsequently revised their new pharmaceutical patent systems in the 2000s. In an ESRC-funded project “TRIPS Implementation and Secondary Pharmaceutical Patenting” he examines how developing countries’ new pharmaceutical patent systems function in practice. Ken also works on the political economy of health and pharmaceutical policies, the dynamics of “North-South” trade agreements, and changing patterns of government-business relations and democratization.  From 2011-2020, he was one of the Managing Editors of  The Journal of Development Studies . Expertise:  Latin America; World Trade Organization (WTO); debt and developing countries; industrial policy; intellectual property rights; international institutions; patents; pharmaceuticals; politics; trade and industrial strategy

Dr Jennifer Gill is an Associate Director at the  Medical Technology Research Group  (MTRG) at the London School of Economics and Political Science. She has a BSc in Pharmacology from The University of Aberdeen and a PhD in Genetics from The University of Edinburgh. Before joining LSE, Jennifer worked as a Senior Postdoctoral Research Associate in the Research Department of Pharmacy Practice and Policy at University College London, acting as an academic consultant for a number of large, multinational companies. Working on the border of academia and consultancy has given Jennifer a unique insight into project management, health communication and knowledge transfer in numerous areas of public health and pharmacy policy, including issues around population ageing, the burden of chronic pain, the future of cancer treatment, MS and medicines access. At LSE, Jennifer has worked with a number of pharmaceutical companies to analyse the use of real world evidence in decision-making across Europe, determine levels of implementation and resulting impact of external reference pricing within and across borders and develop the largest global survey of those with hepatocellular carcinoma in order to better understand the patient journey. Expertise:  pharmacology; genetics; project management; health communication; knowledge transfer; public health; pharmacy policy; chronic pain; population ageing; cancer; MS

Matteo M Galizzi is Associate Professor of Behavioural Science and Co-Director of the Executive MSc in Behavioural Science at LSE. He is affiliated to the  Department of Psychological and Behavioural Science , and is in the Steering Groups of the  LSE Global Health Initiative  and of the  LSE Behavioural Science Hub . Matteo is an experimental and behavioural economist conducting randomised controlled experiments in the area of health and public policy. Graduated from University of Pavia (Italy), he holds an MSc in Econometrics and a PhD in Economics from the University of York (UK). He has taken research and teaching positions at the universities of Pavia, York, Varese, Autonoma Barcelona, Brescia, Queen Mary, Durham, and Paris School of Economics. Matteo’s core methodological expertise is in behavioural data linking, i.e. the linkage of behavioural economics field experiments to longitudinal surveys, administrative records, biomarkers banks, mobile and wearable devices, apps, online panels, and other smart data sources. He is interested in exploring the heterogeneous effects, spillover effects, and sustained effects of nudges and other behavioural interventions, especially in health. He is leading an ESRC-funded project linking experimental, survey, administrative, and biomarkers data for a representative sample of the UK population within  Understanding Society , the world-largest household panel. At LSE, Matteo teaches  Research Methods for Behavioural Science ,  Frontiers in Behavioural Science Methods , and  Behavioural Science for Health  at the EMSc in Behavioural Science; and  Experimental Design and Methods for the Behavioural Science  and  Behavioural Science for Health  at the MSc in Behavioural Science. Matteo is the founder/coordinator of the  @LSE Behavioural  Twitter  account , the  Behavioural Experiments in Health Network  ( BEH-net ), and the  Data Linking Initiative in Behavioural Science  ( DLIBS ). He is the LSE local lead of the  UK Reproducibility Network  ( UKRN ). Expertise:  behavioural economics; experimental economics; health economics; experimental design; behavioural experiments in health; behavioural spillovers; behavioural data linking; external validity, generalizability, and replicability of economic experiments

Daniela works as a project manager and researcher at LSE Consulting. She is responsible for writing and coordinating project proposals for a variety of European and UK clients. She establishes new relationships and manages existing ones with academics, experts and partner organisations. She also provides administrative support to the team’s operations. Beyond her business development tasks, she currently works as a project coordinator and as junior expert on human rights and sustainability issues for two Sustainability Impact Assessment (SIA) projects commissioned by DG Trade of the European Commission. Daniela holds an MSc in International Development Management with a focus on Economics (LSE) and a double BA with Honors in Global Affairs/International Relations and Political Science with a focus on Human Rights Law (Eckerd College).